Community Practice Connections™: Optimizing Outcomes in Cold Agglutinin Disease:
Exploring the Impact of Rapid Diagnosis and Emerging Therapeutic Agents

Released On
August 12, 2021

Expires On
August 12, 2022

Media Type
Internet

Completion Time
60 minutes

Specialty
Hematology-Oncology, Rare Diseases

Topic(s)
Blood Disorder, Thermoregulation

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

 

This activity is supported by an educational grant from Sanofi Genzyme.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This educational activity is directed toward medical hematologists and other health care professionals interested in the latest advances in the treatment of patients with CAD. Fellows, researchers, primary care physicians, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of patients with hematologic diseases are also invited to participate.

Program Overview

Cold agglutinin disease (CAD) is a rare autoimmune disease in which exposure to cold temperatures may trigger hemolysis leading to anemia. Symptoms may arise suddenly and can range in occurrence and severity; this can be debilitating and potentially life-threatening. More than half of the affected patients may require transfusions and a majority requires treatment; however, options are limited, and none are specifically approved for CAD. However, novel complement-directed therapies are in development, which hold promise for this autoimmune hemolytic anemia.

This Community Practice Connections™ program provides an in-depth review of some of the key highlights from the live virtual symposium held on June 10, 2021. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with CAD, while placing recent clinical trial data into a clinical context. The program is designed for those who did not attend the live meeting and would help to reinforce learnings for those who did.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the clinical burden of cold agglutinin disease
  • Explain how the complement system is implicated in the onset of cold agglutinin disease
  • Apply diagnostic criteria to facilitate an accurate and timely diagnosis of cold agglutinin disease
  • Identify complement-mediated therapies for the treatment of cold agglutinin disease based on current and emerging evidence

Faculty

FACULTY_NAME

Alexander Röth, MD

Department of Hematology and
Stem Cell Transplantation
West German Cancer Center
University Hospital Essen
University Duisburg-Essen
Essen, Germany

FACULTY_NAME

Sigbjørn Berentsen, MD, PhD

Consultant Hematologist and Senior Researcher
Department of Research and Innovation
Helse Fonna HF, Haugesund Hospital
Haugesund, Norway

FACULTY_NAME

Wilma Barcellini, MD

Director, UOS Physiopathology of Anemias
UO Hematology – Granelli Pavilion
IRCCS Ca’ Granda Foundation
Maggiore Policlinico Hospital
Milan, Italy

FACULTY_NAME

Catherine M. Broome, MD

Associate Professor of Medicine
MedStar Georgetown University Lombardi Cancer Center
Washington, DC

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.

Alexander Röth, MD

  • Grant Research Support: Hoffmann-La Roche
  • Consultant: Alexion Pharmaceuticals, Apellis Pharmaceuticals, BioCryst Pharmaceuticals, Novartis Pharmaceuticals Corporation, Hoffmann-La Roche, Sanofi.

Sigbjørn Berentsen, MD, PhD

  • Consultant: Apellis Pharmaceuticals, Bioverativ (a Sanofi Genzyme company), Momenta Pharmaceuticals, Sobi
  • Other: Lecture honoraria: Apellis Pharmaceuticals, Bioverativ (a Sanofi Genzyme company), Janssen-Cilag.

Wilma Barcellini, MD

  • Consultant: Apellis Pharmaceuticals, Incyte Corporation, Sanofi.

Catherine M. Broome, MD

  • Other: Apellis Pharmaceuticals Advisory Board.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Instructions for Participation and Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.
You may immediately download your certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.